DGAP-News
CEVEC introduces CAP(R)Go expression system for scalable production of tailor-made glycoproteins
DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Product
Launch/Miscellaneous
CEVEC introduces CAP(R)Go expression system for scalable production of
tailor-made glycoproteins
01.06.2015 / 09:00
---------------------------------------------------------------------
CEVEC introduces CAP(R)Go expression system for scalable production of
tailor-made glycoproteins
Cologne, Germany, June 1, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC), a
global solution and service provider for the production of
biopharmaceuticals based on a unique human cellular expression system,
today announced the introduction of the technology platform CAP(R)Go for
the fully scalable production of tailor-made glycosylated recombinant
proteins, based on the Company's proprietary CAP(R) technology.
CAP(R)Go technology - tailor-made glycosylation of recombinant proteins
With the CAP(R)Go technology, CEVEC addresses an increasing need in the
pharmaceutical and biotechnology industries for the manufacturing of
difficult to express therapeutic glycoproteins with tailor-made or fully
human glycosylation patterns for significantly improved physicochemical and
pharmacological properties.
CEVEC's CAP(R)Go expression platform comprises a comprehensive portfolio of
glyco-optimized human suspension cell lines that differ in their
glycosylation capabilities and allows for the recombinant production of a
variety of complexly glycosylated proteins such as high molecular mass
multimeric proteins including plasma proteins, coagulation factors,
cytokines and antibodies.
In previous studies, CAP(R)Go has proven to enhance the activity, stability
and serum half-life of several candidate proteins. Depending on the
selected CAP(R)Go cell line, the expressed protein showed: increased
sialylation for improved half-life; homogenous, serum-like O-glycan
structures and/or defined N-glycan antennarity, just to name a few.
Therapeutic proteins expressed on conventional mammalian expression
platforms like CHO (Chinese hamster ovary) or HEK293 cells (human embryonic
kidney cells), by contrast, often do not match the glycosylation and
pharmacokinetic profiles of their plasma-purified counterparts. The
CAP(R)Go technology provides a highly economic way to manufacture
glyco-optimized proteins with up to 10 fold higher yields than conventional
cell lines and offers cost efficient large scale production.
CEVEC introduces CAP(R)Go expression system for scalable production of
tailor-made glycoproteins
Cologne, Germany, June 1, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC), a
global solution and service provider for the production of
biopharmaceuticals based on a unique human cellular expression system,
today announced the introduction of the technology platform CAP(R)Go for
the fully scalable production of tailor-made glycosylated recombinant
proteins, based on the Company's proprietary CAP(R) technology.
CAP(R)Go technology - tailor-made glycosylation of recombinant proteins
With the CAP(R)Go technology, CEVEC addresses an increasing need in the
pharmaceutical and biotechnology industries for the manufacturing of
difficult to express therapeutic glycoproteins with tailor-made or fully
human glycosylation patterns for significantly improved physicochemical and
pharmacological properties.
CEVEC's CAP(R)Go expression platform comprises a comprehensive portfolio of
glyco-optimized human suspension cell lines that differ in their
glycosylation capabilities and allows for the recombinant production of a
variety of complexly glycosylated proteins such as high molecular mass
multimeric proteins including plasma proteins, coagulation factors,
cytokines and antibodies.
In previous studies, CAP(R)Go has proven to enhance the activity, stability
and serum half-life of several candidate proteins. Depending on the
selected CAP(R)Go cell line, the expressed protein showed: increased
sialylation for improved half-life; homogenous, serum-like O-glycan
structures and/or defined N-glycan antennarity, just to name a few.
Therapeutic proteins expressed on conventional mammalian expression
platforms like CHO (Chinese hamster ovary) or HEK293 cells (human embryonic
kidney cells), by contrast, often do not match the glycosylation and
pharmacokinetic profiles of their plasma-purified counterparts. The
CAP(R)Go technology provides a highly economic way to manufacture
glyco-optimized proteins with up to 10 fold higher yields than conventional
cell lines and offers cost efficient large scale production.